Zukunftsfonds Heilbronn
Edisonstr. 19, Heilbronn, Baden-Württemberg, 74076, Germany
Overview
Zukunftsfond Heilbronn supports as a regional venture capital fund in the very busy South of Germany, the development of young innovative companies from start-up to matural stage. The investment philosophy of Zukunfsfonds Heilbronn is simple: they are investing in young, promising companies with innovative ideas, which have a good market potential and are controlled by a prominent management-team. They are investing in an early stage – from the seed, beyond the start-up to the phase of expansion – in fact as long as it is reasonable for both parties.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Finance
- Financial Services
Investment portfolio
- Eleva
Led · Equity · Jan 2021
Eleva leverages a moss-based production platform to manufacture biologics such as antibodies, replacement enzymes and fusion toxins. The company has developed drug candidates into clinical phases. Eleva secured up to €60m in funding from Zukunftsfonds Heilbronn. The proceeds are intended to advance its drug candidate CPV-101 to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. The financing announcement coincided with the appointment of Dr. Ralf Smit as Chief Business Officer; he previously advised Eleva and brings over 25 years of business development and commercialization experience with Roche and BioStrat.